A Phase 3 interventional study of cabozantinib and prednisone in Prostate Cancer, Castration Resistant Prostate Cancer and Pain, sponsored by Exelixis. Completed at 264 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-14.
Sponsored by Exelixis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing cabozantinib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 2 of them phase 3. cabozantinib · Prostatic Neoplasms.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 6 that started in 2012, is one of 4 in phase 3, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 23 studies testing cabozantinib in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+ · Men only
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
Ages 18+
Exelixis · Sites in United States
By country, each count listing its studies:
cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cabozantinib is the treatment under test here. Read study by study →
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 4
First in 2009; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,028 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 33 across the 23 interventional studies. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 23 have an industry lead sponsor. The 10 most frequent:
Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Exelixis has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing cabozantinib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05168618University of UtahCabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | 2026-11 |
| NCT05613894University of UtahDose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12 |
| NCT03866382National Cancer Institute (NCI)Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | 2027-02-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing cabozantinib in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
Drug: cabozantinib
Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
Drug: prednisone
Tablets taken orally once-daily
Also known as: XL184
Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Overall Survival (OS)
The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred.
Time frame: OS was measured from the time of randomization until 614 events, approximately 24 months after study start
Bone Scan Response (BSR)
BSR is defined as \>=30% reduction in the bone scan lesion area (BSLA) compared with baseline. Confirmation of bone scan was not required for response or progression. Bone scans were evaluated by an independent radiology facility (IRF) for response.
Time frame: BSR was measured at the end of Week 12 as determined by the IRF
Progression-free Survival (PFS)
The exploratory analysis of PFS is the time from randomization to date of first documented radiographic progression (bone and/or soft tissue) according to the investigator's assessment or death. PFS was defined per mRECIST 1.1 and included evaluation of measurable, nonmeasurable, target and nontarget lesions. A Kaplan-Meier analysis was performed to estimate the median duration.
Time frame: Duration of PFS was defined as time from the date of randomization to earlier of date of radiographic progression (bone/andor soft tissue) according to the investigator's assessment or death, assessed for up to approximately 24 months
First patient enrolled: 02 July 2012 (first subject randomized), Data cut off date: 07 July 2014
| Milestone | Cabozantinib | Prednisone |
|---|---|---|
| Started | 682 | 346 |
| Completed | 61 | 17 |
| Not completed | 621 | 329 |
| Withdrew: Did not receive study treatment | 2 | 3 |
| Withdrew: Adverse event | 228 | 42 |
| Withdrew: Progressive disease | 132 | 128 |
| Withdrew: Clinical deterioration | 227 | 133 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Physician decision | 9 | 7 |
| Withdrew: Withdrawal by subject | 18 | 14 |
| Withdrew: Sponsor decision | 2 | 0 |
| Withdrew: Started new therapy | 1 | 0 |
| Withdrew: Subject decision | 0 | 1 |
| Withdrew: Dose held >6 weeks | 0 | 1 |
The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred.
| months | Cabozantinib | Prednisone |
|---|---|---|
| Overall Survival (OS) | 11.0 (10.09 to 11.63) | 9.8 (9.00 to 11.53) |
BSR is defined as \>=30% reduction in the bone scan lesion area (BSLA) compared with baseline. Confirmation of bone scan was not required for response or progression. Bone scans were evaluated by an independent radiology facility (IRF) for response.
| percentage of participants | Cabozantinib | Prednisone |
|---|---|---|
| Bone Scan Response (BSR) | 42 (38 to 46) | 3 (1 to 5) |
The exploratory analysis of PFS is the time from randomization to date of first documented radiographic progression (bone and/or soft tissue) according to the investigator's assessment or death. PFS was defined per mRECIST 1.1 and included evaluation of measurable, nonmeasurable, target and nontarget lesions. A Kaplan-Meier analysis was performed to estimate the median duration.
| months | Cabozantinib | Prednisone |
|---|---|---|
| Progression-free Survival (PFS) | 5.6 (5.49 to 5.62) | 2.8 (2.79 to 2.86) |
Collected over Up to 92 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cabozantinib | — | 420/681 (61.7%) | 675/681 (99.1%) |
| Prednisone | — | 181/342 (52.9%) | 332/342 (97.1%) |
| Event | Cabozantinib | Prednisone |
|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 52/681 | 27/342 |
| General physical health deteriorationGeneral disorders | 52/681 | 22/342 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 42/681 | 3/342 |
| AnaemiaBlood and lymphatic system disorders | 32/681 | 16/342 |
| VomitingGastrointestinal disorders | 28/681 | 6/342 |
| PneumoniaInfections and infestations | 17/681 | 12/342 |
| Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/681 | 12/342 |
| NauseaGastrointestinal disorders | 23/681 | 6/342 |
| Bone painMusculoskeletal and connective tissue disorders | 15/681 | 11/342 |
| FatigueGeneral disorders | 20/681 | 3/342 |
| Event | Cabozantinib | Prednisone |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 407/681 | 99/342 |
| NauseaGastrointestinal disorders | 390/681 | 102/342 |
| DiarrhoeaGastrointestinal disorders | 349/681 | 68/342 |
| FatigueGeneral disorders | 338/681 | 119/342 |
| VomitingGastrointestinal disorders | 271/681 | 67/342 |
| Weight decreasedInvestigations | 237/681 | 41/342 |
| AstheniaGeneral disorders | 228/681 | 63/342 |
| ConstipationGastrointestinal disorders | 227/681 | 100/342 |
| AnaemiaBlood and lymphatic system disorders | 203/681 | 111/342 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 200/681 | 5/342 |
| Age, Categorical(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 165 | 97 | 262 |
| >=65 years | 517 | 249 | 766 |
| Sex: Female, Male(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 682 | 346 | 1028 |
| Race (NIH/OMB)(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 14 | 6 | 20 |
| White | 520 | 265 | 785 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 146 | 74 | 220 |
| Region of Enrollment(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| North America | 119 | 63 | 182 |
| Europe | 528 | 256 | 784 |
| Australia | 35 | 27 | 62 |
| Prior cabazitaxel (per CRF)(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| Yes | 261 | 132 | 393 |
| No | 421 | 214 | 635 |
| Brief Pain Inventory (BPI) Item 3 (per CRF)(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| <4 | 389 | 196 | 585 |
| ≥4 | 284 | 148 | 432 |
| Missing | 9 | 2 | 11 |
| ECOG Performance Status (per CRF)(participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| 0/1 (asymptomatic or symptomatic but ambulatory) | 605 | 303 | 908 |
| 2 (ambulatory but can't carry out work activities) | 76 | 43 | 119 |
| Missing | 1 | 0 | 1 |
| Opioid narcotic use within 24 hours (per solicited oploid CRF)(Participants) | Cabozantinib | Prednisone | Total |
|---|---|---|---|
| Count of participants | 454 | 228 | 682 |
8 further baseline measures are reported on the registry.
Showing the first 100 of 264 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2012, a primary completion of Sep 2014 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabozantinib